DelistingJun 4, 2026, 04:07 PM
Zhengye Biotechnology Receives Nasdaq Bid Price Deficiency Notice
AI Summary
Zhengye Biotechnology Holding Limited announced it received a notice from Nasdaq on May 29, 2026, indicating non-compliance with the minimum bid price requirement. The company's Class A ordinary shares traded below $1.00 for 30 consecutive business days. Zhengye Biotechnology has a 180-calendar-day compliance period, until November 25, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company's business operations are not affected, and its shares will continue to trade under the symbol "ZYBT" without immediate delisting.
Key Highlights
- Zhengye Biotechnology received a Nasdaq notification on May 29, 2026, regarding minimum bid price deficiency.
- The company's Class A ordinary shares traded below $1.00 for 30 consecutive business days.
- Zhengye Biotechnology has 180 calendar days, until November 25, 2026, to regain compliance.
- To regain compliance, the closing bid price must be at least $1.00 for 10 consecutive business days.
- The company may be eligible for an additional 180-day grace period if certain conditions are met.
- Zhengye Biotechnology may consider a reverse share split to cure the deficiency.
- The notification does not result in immediate delisting; shares continue to trade under "ZYBT".
Price Impact
More from ZYBT